

Brain tumor vaccine has promising results

22 November 2006

U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.

Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.

The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.

The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology.

Copyright 2006 by United Press International

APA citation: Brain tumor vaccine has promising results (2006, November 22) retrieved 5 August 2022 from <https://medicalxpress.com/news/2006-11-brain-tumor-vaccine-results.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.